CA2132512A1 - Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs - Google Patents
Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifsInfo
- Publication number
- CA2132512A1 CA2132512A1 CA002132512A CA2132512A CA2132512A1 CA 2132512 A1 CA2132512 A1 CA 2132512A1 CA 002132512 A CA002132512 A CA 002132512A CA 2132512 A CA2132512 A CA 2132512A CA 2132512 A1 CA2132512 A1 CA 2132512A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- controlled release
- active ingredient
- composition used
- bioadhesive pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs de manière locale à travers la cavité buccale ou systémique à travers une muqueuse caractérisée en ce qu'elle est composée d'un principe actif, d'un composé (A), d'un composé (B) et d'excipients tels que définis dans la description.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9311259A FR2710265B1 (fr) | 1993-09-22 | 1993-09-22 | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
FR93.11259 | 1993-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2132512A1 true CA2132512A1 (fr) | 1995-03-23 |
CA2132512C CA2132512C (fr) | 2001-07-03 |
Family
ID=9451097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002132512A Expired - Fee Related CA2132512C (fr) | 1993-09-22 | 1994-09-20 | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
Country Status (14)
Country | Link |
---|---|
US (1) | US5672356A (fr) |
EP (1) | EP0649650B1 (fr) |
JP (1) | JPH07173077A (fr) |
AT (1) | ATE197899T1 (fr) |
AU (1) | AU672526B2 (fr) |
CA (1) | CA2132512C (fr) |
DE (1) | DE69426382T2 (fr) |
DK (1) | DK0649650T3 (fr) |
ES (1) | ES2154288T3 (fr) |
FR (1) | FR2710265B1 (fr) |
GR (1) | GR3035308T3 (fr) |
NZ (1) | NZ264500A (fr) |
PT (1) | PT649650E (fr) |
ZA (1) | ZA947402B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030013A1 (fr) * | 1995-03-29 | 1996-10-03 | Minnesota Mining And Manufacturing Company | Apport de melatonine a travers les muqueuses pour la prevention de la migraine |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2742989B1 (fr) * | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
US6423345B2 (en) | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
US6319513B1 (en) | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
US6887493B2 (en) * | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
FR2834894B1 (fr) * | 2002-01-21 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de piribedil |
FR2834896B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'ivabradine |
FR2834890B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'agomelatine |
ES2209649B1 (es) * | 2002-12-09 | 2005-03-16 | Carlos Arana Molina (Titular Al 25%) | Utilizacion de la melatonina para la higiene bucodental para uso humano y veterinario como producto activo. |
JP5137286B2 (ja) * | 2003-06-10 | 2013-02-06 | 帝國製薬株式会社 | フェンタニル含有口腔粘膜貼付剤 |
FR2857594B1 (fr) * | 2003-07-17 | 2005-09-16 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
US20060062833A1 (en) * | 2004-09-22 | 2006-03-23 | Cima Labs Inc. | Wound dressing |
EP2019679B1 (fr) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Inhibiteurs de transport de glucose et procédés d'utilisation |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US20080171085A1 (en) * | 2007-01-11 | 2008-07-17 | Natrol, Inc. | Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration |
RU2492175C2 (ru) | 2007-04-02 | 2013-09-10 | Теракос, Инк. | Бензиловые производные гликозидов и способы их применения |
EP3318562A3 (fr) | 2007-08-23 | 2018-09-12 | Theracos Sub, LLC | Dérivés de benzylbenzène et procédés d'utilisation |
UA104594C2 (en) | 2008-07-15 | 2014-02-25 | Теракос, Инк. | Deuterated benzylbenzole derivatives and using thereof |
DK2324002T3 (en) | 2008-08-22 | 2016-12-19 | Theracos Sub Llc | Methods of making of sglt2 inhibitors |
EP3037421A3 (fr) | 2008-11-25 | 2016-11-30 | University Of Rochester | Inhibiteurs de mlk et procédés d'utilisation |
NZ598762A (en) * | 2009-09-04 | 2014-11-28 | Robert J Davis | Reversible oral adhesive gel |
WO2011149950A2 (fr) | 2010-05-24 | 2011-12-01 | University Of Rochester | Hétéroaryles bicycliques formant inhibiteurs de la kinase et procédés d'utilisation |
WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
EP3502236B1 (fr) | 2011-02-18 | 2023-08-23 | The Scripps Research Institute | Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin de cellules myélinisantes |
US8524664B2 (en) | 2011-06-02 | 2013-09-03 | Colorado Seminary, Which owns and Operates The Univeristy of Denver | Methods of treating overproduction of cortisol using ACTH antagonist peptides |
WO2014085795A1 (fr) | 2012-11-30 | 2014-06-05 | University Of Rochester | Inhibiteurs de kinase de lignage mixte pour des thérapies pour le vih/sida |
BR102014028009B1 (pt) | 2014-11-10 | 2023-04-18 | Universidade Federal De Pelotas | Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos |
WO2017147887A1 (fr) * | 2016-03-03 | 2017-09-08 | Boai Nky Pharmaceuticals Ltd. | Copolymères fins et uniformes de sels inorganiques d'éther vinylique de méthyle-acide maléique, et leur utilisation dans les applications de soins buccaux et pharmaceutiques |
CN108535249B (zh) * | 2018-04-25 | 2021-02-26 | 郑州贝贝生物科技有限公司 | 农药残留快速检测点卡 |
WO2022224464A1 (fr) * | 2021-04-21 | 2022-10-27 | 順也 藤森 | Composition phytochimique |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4553973A (en) * | 1982-07-12 | 1985-11-19 | Alza Corporation | Process for preparing osmotic device |
DE3580384D1 (de) * | 1984-04-09 | 1990-12-13 | Toyo Boseki | Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle. |
JPS6117510A (ja) * | 1984-07-03 | 1986-01-25 | Toyobo Co Ltd | 口腔粘膜適用徐放性ニフエジピン製剤 |
DE3686275T2 (de) * | 1985-01-11 | 1993-03-18 | Teijin Ltd | Praeparate mit verzoegerter freisetzung. |
US4772470A (en) * | 1985-04-27 | 1988-09-20 | Nitto Electric Industrial Co., Ltd. | Oral bandage and oral preparations |
US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4755386A (en) * | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
JPS63311960A (ja) * | 1987-06-16 | 1988-12-20 | Sekisui Chem Co Ltd | 医療用粘着剤組成物及びその製造方法 |
US4948580A (en) * | 1988-12-08 | 1990-08-14 | E. R. Squibb & Sons, Inc. | Muco-bioadhesive composition |
US5032384A (en) * | 1989-01-27 | 1991-07-16 | Block Drug Company, Inc. | Compositions and method for the treatment of disease |
US5112620A (en) * | 1990-09-20 | 1992-05-12 | Mikkur, Inc. | Polyethylene glycol ointment for apthous ulcers |
IT1251114B (it) * | 1991-07-26 | 1995-05-04 | Farcon Ag | Forme farmaceutiche antivirali per applicazione vaginale |
US5385729A (en) * | 1991-08-01 | 1995-01-31 | Colgate Palmolive Company | Viscoelastic personal care composition |
US5292517A (en) * | 1992-02-25 | 1994-03-08 | Allergan, Inc. | pH sensitive, reversible gelling, copolymeric erodible drug delivery system |
US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
-
1993
- 1993-09-22 FR FR9311259A patent/FR2710265B1/fr not_active Expired - Fee Related
-
1994
- 1994-09-15 EP EP94402060A patent/EP0649650B1/fr not_active Expired - Lifetime
- 1994-09-15 ES ES94402060T patent/ES2154288T3/es not_active Expired - Lifetime
- 1994-09-15 PT PT94402060T patent/PT649650E/pt unknown
- 1994-09-15 DK DK94402060T patent/DK0649650T3/da active
- 1994-09-15 DE DE69426382T patent/DE69426382T2/de not_active Expired - Fee Related
- 1994-09-15 AT AT94402060T patent/ATE197899T1/de not_active IP Right Cessation
- 1994-09-20 CA CA002132512A patent/CA2132512C/fr not_active Expired - Fee Related
- 1994-09-20 AU AU74110/94A patent/AU672526B2/en not_active Ceased
- 1994-09-21 NZ NZ264500A patent/NZ264500A/en unknown
- 1994-09-21 JP JP6226876A patent/JPH07173077A/ja active Pending
- 1994-09-21 US US08/309,930 patent/US5672356A/en not_active Expired - Fee Related
- 1994-09-22 ZA ZA947402A patent/ZA947402B/xx unknown
-
2001
- 2001-01-26 GR GR20010400133T patent/GR3035308T3/el not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030013A1 (fr) * | 1995-03-29 | 1996-10-03 | Minnesota Mining And Manufacturing Company | Apport de melatonine a travers les muqueuses pour la prevention de la migraine |
US5688520A (en) * | 1995-03-29 | 1997-11-18 | Minnesota Mining And Manufacturing Company | Transmucosal delivery of melatonin for prevention of migraine |
Also Published As
Publication number | Publication date |
---|---|
PT649650E (pt) | 2001-05-31 |
DE69426382D1 (de) | 2001-01-11 |
ATE197899T1 (de) | 2000-12-15 |
AU7411094A (en) | 1995-04-06 |
EP0649650A1 (fr) | 1995-04-26 |
FR2710265A1 (fr) | 1995-03-31 |
JPH07173077A (ja) | 1995-07-11 |
DK0649650T3 (da) | 2001-02-12 |
GR3035308T3 (en) | 2001-04-30 |
ZA947402B (en) | 1995-05-15 |
ES2154288T3 (es) | 2001-04-01 |
AU672526B2 (en) | 1996-10-03 |
NZ264500A (en) | 1996-07-26 |
FR2710265B1 (fr) | 1995-10-20 |
US5672356A (en) | 1997-09-30 |
DE69426382T2 (de) | 2001-06-21 |
EP0649650B1 (fr) | 2000-12-06 |
CA2132512C (fr) | 2001-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2132512A1 (fr) | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs | |
AU7549696A (en) | Bioadhesive pharmaceutical composition for the controlled release of active principles | |
TW273550B (fr) | ||
CA2111002A1 (fr) | Formulations d'aerosol sans chlorofluorocarbure | |
EP0995434A3 (fr) | Formulations d'aérosols à usage médical | |
CA2163003A1 (fr) | Agent de solubilisation et preparation a usage externe a base de cet agent | |
CA2179540A1 (fr) | Composition a liberation acceleree contenant de la bromocryptine | |
EP0595133A3 (fr) | Prodroques, leur préparation, et utilisation comme médicaments | |
AU6569694A (en) | Active substance-containing plaster | |
CA2116238A1 (fr) | 1 .alpha.-hydroxyprevitamine d par voie orale | |
AU2807195A (en) | Hair growing agent | |
CA2093282A1 (fr) | Dispositif d'administration intra-buccale de medicaments | |
AU3354895A (en) | Novel medicinal use of 5ht3 antagonist | |
AU4297089A (en) | Dispersable formulation of diclofenac in free acid form | |
AU4434189A (en) | An anti-human immunodeficiency virus composition | |
WO1998010762A3 (fr) | Formulation a liberation lente de monohydrochlorure de [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile | |
AU1811695A (en) | Antitussive composition containing an antitussive and benzydamine | |
AU4353996A (en) | Pharmaceutical tablet formulations for direct compression | |
AU674379B2 (en) | Antitussive | |
ES2097618T3 (es) | Formulacion de aerosol a base de fusafungina. | |
CA2057456A1 (fr) | Produit pharmaceutique contre la depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |